TrialSignal
Clinical trial intelligence report
Nimotuzumab in Combination With Radiochemotherapy for Patients With Stage IIIA/IIIB Non-small Cell Lung Cancer
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT02549261
Status
UNKNOWN
Phase
NA
Sponsor
Biotech Pharmaceutical Co., Ltd.
Executive brief
Investment-Ready Snapshot
Nimotuzumab (hR3) is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR). Clinical efficacy has been shown in adult with head and neck cancer. The study assessed the efficacy and safety of the combination of Nimotuzumab administered concomitantly with chemoradiotherapy in patients with NSCLC .There is a tolerance trial of Nimotuzumab in Combination With Radiochemotherapy treatment before the randomization,double blind,muti-center sites trial of this treatment.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT02549261
Indication
Non-small Cell Lung Cancer
Modality
monoclonal antibody
Target
nimotuzumab, Cisplatin, Etoposide, radiotherapy
Intervention
nimotuzumab, Cisplatin, Etoposide, radiotherapy
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.